Mablink Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 34

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $278M

Mablink General Information

Description

Operator of a biotechnology company intended to develop antibody-drug-conjugates drugs to fight cancer. The company helps to design homogenous, plasma-stable conjugates with a high drug-antibody ratio while retaining original pharmacological properties, enabling healthcare professionals to provide patients with new and improved treatment options for cancer.

Contact Information

Website
www.mablink.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 31 Rue Gorge de Loup
  • 69009 Lyon
  • France
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 31 Rue Gorge de Loup
  • 69009 Lyon
  • France

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mablink Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 01-Dec-2023 $278M Completed Generating Revenue
6. Early Stage VC (Series A) 31-Jul-2022 Completed Generating Revenue
5. Seed Round 27-Apr-2021 Completed Pre-Clinical Trials
4. Seed Round 19-Sep-2019 Completed Pre-Clinical Trials
3. Accelerator/Incubator 15-May-2019 Completed Pre-Clinical Trials
2. Accelerator/Incubator 01-Jan-2019 Completed Startup
1. Grant 01-Jan-2019 $1.71M Completed Startup
To view Mablink’s complete valuation and funding history, request access »

Mablink Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Shares A
S Shares
Ordinary 1,850 $1.019323 $72.4 $72.4 1x $72.4 1.07%
Ordinary 1,670 $1.019323 $9.17 $9.17 1x $9.17 0.97%
To view Mablink’s complete cap table history, request access »

Mablink Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology company intended to develop antibody-drug-conjugates drugs to fight cancer. The company help
Drug Discovery
Lyon, France
34 As of 2023

Oxford, United Kingdom
 

Nijmegen, Netherlands
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Mablink Competitors (22)

One of Mablink’s 22 competitors is Oxford Biotherapeutics, a Private Equity-Backed company based in Oxford, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Oxford Biotherapeutics Private Equity-Backed Oxford, United Kingdom
Byondis Corporation Nijmegen, Netherlands
Vir Biotechnology Formerly VC-backed San Francisco, CA
Meditope Biosciences Formerly VC-backed Pasadena, CA
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 22 competitors. Get the full list »

Mablink Patents

Mablink Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4788379-A1 Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload Pending 02-Oct-2023
US-12419964-B2 Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload Active 02-Oct-2023
US-20250127916-A1 Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload Active 02-Oct-2023
US-20260021194-A1 Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload Pending 02-Oct-2023
WO-2025073812-A1 Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload Inactive 02-Oct-2023 A61K47/68037
To view Mablink’s complete patent history, request access »

Mablink Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mablink Former Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angelor Venture Capital Minority
BigBooster Accelerator/Incubator
Bpifrance Sovereign Wealth Fund Minority
Crédit Agricole Création Venture Capital Minority
Elaia Partners Venture Capital Minority
You’re viewing 5 of 16 investors. Get the full list »

Mablink FAQs

  • When was Mablink founded?

    Mablink was founded in 2018.

  • Where is Mablink headquartered?

    Mablink is headquartered in Lyon, France.

  • What is the size of Mablink?

    Mablink has 34 total employees.

  • What industry is Mablink in?

    Mablink’s primary industry is Drug Discovery.

  • Is Mablink a private or public company?

    Mablink is a Private company.

  • What is the current valuation of Mablink?

    The current valuation of Mablink is .

  • What is Mablink’s current revenue?

    The current revenue for Mablink is .

  • How much funding has Mablink raised over time?

    Mablink has raised $36.4M.

  • Who are Mablink’s investors?

    Angelor, BigBooster, Bpifrance, Crédit Agricole Création, and Elaia Partners are 5 of 16 investors who have invested in Mablink.

  • Who are Mablink’s competitors?

    Oxford Biotherapeutics, Byondis, Vir Biotechnology, Meditope Biosciences, and CytomX Therapeutics are some of the 22 competitors of Mablink.

  • When was Mablink acquired?

    Mablink was acquired on 01-Dec-2023.

  • Who acquired Mablink?

    Mablink was acquired by Lilly USA.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process